Safety and efficacy results from the INJOURNEYTM trial investigating OFEV® (nintedanib) with add-on pirfenidone provide new data to support nintedanib』s key role in IPF
Data from this 12-week study show that the safety and tolerability profile of nintedanib with add-on pirfenidone is in keeping with the known profiles of the individual drugs in patients wit......